Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Jacksonville, FL
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Atlanta, GA
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Rochester, MN
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Reno, NV
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Reno, NV
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
New York, NY
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Chapel Hill, NC
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Durham, NC
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Bethlehem, PA
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Charleston, SC
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Chattanooga, TN
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Houston, TX
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Lubbock, TX
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Lubbock, TX
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Toronto,
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Toronto,
Click here to add this to my saved trials
Ischemic Preconditioning to Prevent Acute Kidney Injury
Ischemic Preconditioning to Prevent Acute Kidney Injury
Status: Enrolling
Updated:  4/2/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
Ischemic Preconditioning to Prevent Acute Kidney Injury
Ischemic Preconditioning to Prevent Acute Kidney Injury
Status: Enrolling
Updated: 4/2/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
PK Study of Intranasal RX0041-002 in Subjects With Severe Renal Impairment and Normal Renal Function
A Phase-1 Study Comparing the Pharmacokinetics of Intranasal RX0041-002 in Subjects With Severe Renal Impairment and Subjects With Normal Renal Function
Status: Enrolling
Updated:  4/4/2018
Comprehensive Clinical Researc
mi
from
Berlin, NJ
PK Study of Intranasal RX0041-002 in Subjects With Severe Renal Impairment and Normal Renal Function
A Phase-1 Study Comparing the Pharmacokinetics of Intranasal RX0041-002 in Subjects With Severe Renal Impairment and Subjects With Normal Renal Function
Status: Enrolling
Updated: 4/4/2018
Comprehensive Clinical Researc
mi
from
Berlin, NJ
Click here to add this to my saved trials
Pilot Study of Taste Sensations in Patients With End-stage Renal Disease on Hemodialysis
Pilot Study of Taste Sensations in Patients With End-stage Renal Disease on Hemodialysis
Status: Enrolling
Updated:  4/4/2018
Purdue University
mi
from
West Lafayette, IN
Pilot Study of Taste Sensations in Patients With End-stage Renal Disease on Hemodialysis
Pilot Study of Taste Sensations in Patients With End-stage Renal Disease on Hemodialysis
Status: Enrolling
Updated: 4/4/2018
Purdue University
mi
from
West Lafayette, IN
Click here to add this to my saved trials
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated:  4/5/2018
Arizona Burn Center
mi
from
Phoenix, AZ
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated: 4/5/2018
Arizona Burn Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated:  4/5/2018
Tampa General Hospital
mi
from
Tampa, FL
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated: 4/5/2018
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated:  4/5/2018
Doctors Hospital-Joseph M Still Burn Center
mi
from
Augusta, GA
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated: 4/5/2018
Doctors Hospital-Joseph M Still Burn Center
mi
from
Augusta, GA
Click here to add this to my saved trials
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated:  4/5/2018
Loyola University Medical Center
mi
from
Maywood, IL
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated: 4/5/2018
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated:  4/5/2018
University of Kansas Hospital
mi
from
Kansas City, KA
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated: 4/5/2018
University of Kansas Hospital
mi
from
Kansas City, KA
Click here to add this to my saved trials
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated:  4/5/2018
The Regional Med Ctr, Memphis
mi
from
Memphis, TN
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated: 4/5/2018
The Regional Med Ctr, Memphis
mi
from
Memphis, TN
Click here to add this to my saved trials
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated:  4/5/2018
University of Texas Southwestern Medical Center-Burn Center Parkland Health
mi
from
Dallas, TX
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated: 4/5/2018
University of Texas Southwestern Medical Center-Burn Center Parkland Health
mi
from
Dallas, TX
Click here to add this to my saved trials
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated:  4/5/2018
U.S. Army Institute of Surgical Research
mi
from
Fort Sam Houston, TX
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated: 4/5/2018
U.S. Army Institute of Surgical Research
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated:  4/5/2018
The Burn Center at Washington Hospital Center
mi
from
Washington,
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated: 4/5/2018
The Burn Center at Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  4/9/2018
UCLA Medical Center
mi
from
Los Angeles, CA
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 4/9/2018
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  4/9/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 4/9/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  4/9/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 4/9/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  4/9/2018
New York University School of Medicine
mi
from
New York, NY
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 4/9/2018
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  4/9/2018
Cleveland Clinic
mi
from
Cleveland, OH
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 4/9/2018
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  4/9/2018
University of Virginia - Nephrology Clinical Research Center
mi
from
Charlottesville, VA
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 4/9/2018
University of Virginia - Nephrology Clinical Research Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  4/9/2018
Medical College of Wisconsin
mi
from
Milwaukee, WI
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 4/9/2018
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  4/9/2018
The Mayo Clinic
mi
from
Rochester, MN
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 4/9/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  4/9/2018
Clinical Advancement Center, PLLC
mi
from
San Antonio, TX
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 4/9/2018
Clinical Advancement Center, PLLC
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  4/9/2018
University of Colorado at Denver
mi
from
Denver, CO
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 4/9/2018
University of Colorado at Denver
mi
from
Denver, CO
Click here to add this to my saved trials
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  4/9/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 4/9/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function
Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function
Status: Enrolling
Updated:  4/9/2018
The Mayo Clinic
mi
from
Rochester, MN
CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function
Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function
Status: Enrolling
Updated: 4/9/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
Status: Enrolling
Updated:  4/9/2018
Orlando Clinical Research Center
mi
from
Orlando, FL
Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
Status: Enrolling
Updated: 4/9/2018
Orlando Clinical Research Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting
A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting
Status: Enrolling
Updated:  4/10/2018
DaVita Clinical Research
mi
from
Lakewood, CO
Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting
A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting
Status: Enrolling
Updated: 4/10/2018
DaVita Clinical Research
mi
from
Lakewood, CO
Click here to add this to my saved trials
Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting
A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting
Status: Enrolling
Updated:  4/10/2018
Orlando Clinical Research Center
mi
from
Orlando, FL
Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting
A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting
Status: Enrolling
Updated: 4/10/2018
Orlando Clinical Research Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting
A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting
Status: Enrolling
Updated:  4/10/2018
DaVita Clinical Research
mi
from
Minneapolis, MN
Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting
A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting
Status: Enrolling
Updated: 4/10/2018
DaVita Clinical Research
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting
A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting
Status: Enrolling
Updated:  4/10/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting
A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting
Status: Enrolling
Updated: 4/10/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting
A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting
Status: Enrolling
Updated:  4/10/2018
Clinical Advancement Center, PLLC
mi
from
San Antonio, TX
Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting
A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting
Status: Enrolling
Updated: 4/10/2018
Clinical Advancement Center, PLLC
mi
from
San Antonio, TX
Click here to add this to my saved trials
Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting
A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting
Status: Enrolling
Updated:  4/10/2018
Univ of Washington
mi
from
Seattle, WA
Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting
A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting
Status: Enrolling
Updated: 4/10/2018
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients
A Plant Based High Protein Diet to Improve Nutritional Outcomes in Dialysis Patients
Status: Enrolling
Updated:  4/12/2018
OCHSNER
mi
from
Baton Rouge, LA
A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients
A Plant Based High Protein Diet to Improve Nutritional Outcomes in Dialysis Patients
Status: Enrolling
Updated: 4/12/2018
OCHSNER
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients
A Plant Based High Protein Diet to Improve Nutritional Outcomes in Dialysis Patients
Status: Enrolling
Updated:  4/12/2018
Davita
mi
from
Baton Rouge, LA
A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients
A Plant Based High Protein Diet to Improve Nutritional Outcomes in Dialysis Patients
Status: Enrolling
Updated: 4/12/2018
Davita
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function
A Phase 1, Open-Label, Parallel-Cohort, Single-Dose Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function
Status: Enrolling
Updated:  4/12/2018
Clinical Pharmacology of Miami
mi
from
Miami, FL
A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function
A Phase 1, Open-Label, Parallel-Cohort, Single-Dose Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function
Status: Enrolling
Updated: 4/12/2018
Clinical Pharmacology of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function
A Phase 1, Open-Label, Parallel-Cohort, Single-Dose Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function
Status: Enrolling
Updated:  4/12/2018
Orlando Clinical Research Center
mi
from
Orlando, FL
A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function
A Phase 1, Open-Label, Parallel-Cohort, Single-Dose Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function
Status: Enrolling
Updated: 4/12/2018
Orlando Clinical Research Center
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function
A Phase 1, Open-Label, Parallel-Cohort, Single-Dose Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function
Status: Enrolling
Updated:  4/12/2018
New Orleans Center for Clinical Research
mi
from
Knoxville, TN
A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function
A Phase 1, Open-Label, Parallel-Cohort, Single-Dose Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function
Status: Enrolling
Updated: 4/12/2018
New Orleans Center for Clinical Research
mi
from
Knoxville, TN
Click here to add this to my saved trials
Hemodialysis-based Interventions to Preserve Cognitive Function
Hemodialysis-based Interventions to Preserve Cognitive Function
Status: Enrolling
Updated:  4/17/2018
Bond St DaVita Dialysis Center
mi
from
Baltimore, MD
Hemodialysis-based Interventions to Preserve Cognitive Function
Hemodialysis-based Interventions to Preserve Cognitive Function
Status: Enrolling
Updated: 4/17/2018
Bond St DaVita Dialysis Center
mi
from
Baltimore, MD
Click here to add this to my saved trials